SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

CorMedix anticipates DefenCath add-on decline in Q2 2027

CorMedix anticipates the DefenCath add-on will decline in Q2 2027 compared with Q1.

CRMD
SquawkNews Desk 1 updates Updated Nov 02, 2026, 12:33 PM UTC

Story updates

12:33:11 PM UTC
SquawkNews
CORMEDIX INC.: ANTICIPATES DEFENCATH ADD-ON WILL INCREASE IN Q3 AND/OR Q4 OF 2027 COMPARED TO Q2

Related stories

BioMar Group Raises 2026 Revenue and EBIT Guidance, Lowers Volume Outlook M impact | EARNINGS | Nov 02, 2026, 02:54 PM UTC BioMar Updates FY2026 EBIT Guidance to DKK 1,290–1,360 Million M impact | EARNINGS | Nov 02, 2026, 02:46 PM UTC US Stocks Rise to Kick Off November US stocks rose at the start of November, with the S&P 500 up 0.5%, the Nasdaq gaining 0.7% and the Dow Jones advancing nearly 400 points, following Friday’s sell-off in AI-related H impact | EARNINGS | Nov 02, 2026, 02:41 PM UTC BioMar Updates FY2026 Revenue Guidance to DKK 17.8–18.6 Billion M impact | EARNINGS | Nov 02, 2026, 02:41 PM UTC BioMar changes full-year 2026 expectations BioMar has announced a change to its full-year 2026 expectations. M impact | EARNINGS | Nov 02, 2026, 02:41 PM UTC Sygnity Reports Preliminary 9-Month EBITDA of About PLN 102.2 Million L impact | EARNINGS | Nov 02, 2026, 02:40 PM UTC